Furthermore, oNKord® is highly cytotoxic against solid tumor targets such as cervical cancer cells, in which killing was independent of HLA expression levels, tumor histology and HPV types (114), or colorectal cancer cells, in which killing was independent of tumor EGFR levels, and RAS and RAF mutations (115), thus paving the way for oNKord® as immunotherapy for advanced solid tumors. This evidence concerns the gene EGFR and colorectal cancer.